雷帕鸣西罗莫司片纳入医保了吗

It is an immunosuppressant whose mechanism of action is different from other immunosuppressants. In addition, rapamycin also inhibits the production of antibodies. In cells, rapamycin sirolimus tablets combine with the immunophilic factor FK-binding protein-12 (FKBP-12) to form an immunosuppressive complex, but this complex does not affect the activity of calcineurin.

Animal experiments show that rapamin sirolimus tablets can prolong the survival (period) of allogeneic transplants (kidney, heart, skin, pancreatic islets, small intestine, pancreaticoduodenum and bone marrow) in mice, rats, pigs or primates; it can reverse acute rejection in rats with heart and kidney allografts.

It has been clinically proven that patients benefit from taking 2 mg rapamin sirolimus tablets oral solution and 2 mg rapamin sirolimus tablets in clinical equivalents. Therefore, patients can interchange the same amounts when actually taking the medication. For new kidney transplant recipients, it is recommended that rapamycin sirolimus tablets be used in combination with cyclosporine and corticosteroids. The loading dose of rapamin sirolimus tablets should be taken for the first time, that is, 3 times the maintenance dose. The recommended loading dose for kidney transplant patients is 6mg and the maintenance dose is 2mg/day, that is, 2 tablets per day. In order to maintain the plasma concentration of rapamin and sirolimus tablets within the target range, the plasma concentration of rapamin and sirolimus tablets should be monitored.

Treatment with rapamycin sirolimus tablets may cause hyperlipidemia and may increase blood lipids (cholesterol and triglycerides). Patients with hyperlipidemia should use this drug with caution. Patients should monitor cholesterol/lipids while receiving rapamycin sirolimus; if hyperlipidemia occurs, follow current management guidelines (diet, exercise, lipid-lowering agents). Antihyperlipidemic treatments may not be effective in achieving normal levels.

Is it covered by medical insurance? It is understood that Rapamin sirolimus tablets have been included in the National Medical Insurance Catalog (Category B) and are medical insurance drugs. However, the reimbursement ratios vary from place to place. It is recommended that patients consult the local medical insurance bureau.

Recommended related hot articles: /newsDetail/80157.html